Investigational drug · Phase 2
VEGF antibody
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Hepatocellular Carcinoma, Advanced Colorectal Cancer.
Phase 2Last checked: Nov 20, 2026Latest source record: Aug 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
872
Any phase or sponsor naming "VEGF antibody"
First trial start
2026
Apr 8, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "VEGF antibody", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hepatocellular Carcinoma
- Advanced Colorectal Cancer
Approved drugs for the same conditions: Colorectal cancer · Liver cancer (hepatocellular carcinoma) · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "VEGF antibody" as an intervention, largest first.
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerPivotal-lookingRecruiting
QuantumLeap Healthcare CollaborativeAcademic, hospital or other
NCT01042379 · 5,000 participants (planned) · Start Mar 1, 2010 · Primary completion Dec 2030
Drug: Standard Therapy; AMG 386 with or without Trastuzumab and 44 more · For: Breast Neoplasms; Breast Cancer; Breast Tumors and 8 more
Sites: Birmingham, Alabama; Scottsdale, Arizona; Tucson, Arizona · 42 sites in all
- Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast CancerPivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT00433511 · 4,994 participants · Start Nov 2, 2007 · Primary completion Jan 7, 2014
Drug: Bevacizumab; Cyclophosphamide and 2 more · For: Breast Adenocarcinoma
Sites: Anniston, Alabama; Birmingham, Alabama; Mobile, Alabama · 842 sites in all
- Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon CancerPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT00096278 · 2,710 participants · Start Sep 15, 2004 · Primary completion Mar 12, 2009
Drug: Bevacizumab; Fluorouracil and 2 more · For: Colon Adenocarcinoma; Stage IIA Colon Cancer AJCC v7; Stage IIB Colon Cancer AJCC v7 and 4 more
Sites: Pittsburgh, Pennsylvania
BayerBayer (BAYRY)
NCT01447043 · 2,609 participants · Start Jan 2009 · Primary completion Aug 2011
Drug: Ranibizumab · For: Ophthalmology, Macular Degeneration
Sites: Many Locations, Australia; Many Locations, Canada; Many Locations, France · 10 sites in all
- Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon CancerPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT00217737 · 2,431 participants · Start Sep 6, 2005 · Primary completion Feb 22, 2024
Drug: Bevacizumab; Fluorouracil and 2 more · For: Colon Adenocarcinoma; Stage IIA Colon Cancer AJCC v7; Stage IIB Colon Cancer AJCC v7 and 1 more
Sites: Anniston, Alabama; Birmingham, Alabama; Huntsville, Alabama · 928 sites in all
- Combination Chemotherapy and Bevacizumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Colorectal CancerPivotal-lookingTerminated
National Cancer Institute (NCI)NIH
NCT00070122 · 2,200 participants · Start Apr 2004 · Primary completion Jan 2007
Drug: oxaliplatin; leucovorin calcium and 3 more · For: Adenocarcinoma of the Colon; Adenocarcinoma of the Rectum; Recurrent Colon Cancer and 5 more
Sites: San Antonio, Texas
- Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube CancerPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT00262847 · 1,873 participants · Start Sep 2005 · Primary completion Nov 2010
Drug: Bevacizumab; Carboplatin and 1 more · For: Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma and 24 more
Sites: Anniston, Alabama; Birmingham, Alabama; Huntsville, Alabama · 632 sites in all
CCTU- Cancer ThemeAcademic, hospital or other
NCT04107168 · 1,800 participants (planned) · Start Jul 8, 2020 · Primary completion Jul 8, 2024
Drug: Nivolumab; Pembrolizumab and 5 more · For: Melanoma; Renal Cancer; Lung Cancer
Sites: Bath, United Kingdom; Bournemouth, United Kingdom; Bristol, United Kingdom · 13 sites in all
- FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcomaPivotal-lookingRecruiting
University of BirminghamAcademic, hospital or other
NCT04625907 · 1,672 participants (planned) · Start Sep 17, 2020 · Primary completion Jun 2030
Drug: Irinotecan; Actinomycin D and 7 more · For: Rhabdomyosarcoma
Sites: Brisbane, Australia; Camperdown, Australia; Clayton, Australia · 128 sites in all
First Affiliated Hospital of Wenzhou Medical UniversityAcademic, hospital or other
NCT06119347 · 1,581 participants · Start Jan 1, 2020 · Primary completion Jun 30, 2023
Drug: AntiVEGF; ICIs · For: AKI Incidence of Cancer Patients Receiving AntiVEGF or ICIs
Sites: Wenzhou, China
Newest research
PubMed records naming it or its code names, newest first.
- Hypoxia-activated microglia promote pathological angiogenesis via an FN/ITGB3/FAK/Akt pathway.
Hao LC, Li DH, Zhang K, et al. · Int J Ophthalmol 2026
- A patent review of antiߛVEGF antibodies for the treatment of ocular diseases (2020-present).
Panos GD · Expert Opin Ther Pat 2026
- Venousization enables angiogenesis in the absence of VEGFR signalling.
Garcia-Gonzalez I, Rocha SF, Oliveira FV, et al. · Nature 2026
- Optimizing the co-assembly of hydrophobic amino acid-modified hexahistidine and bevacizumab for near-complete inhibition of corneal neovascularization.
Ye W, Jiang T, Tang B, et al. · Acta Biomater 2026
- An integrated deep learning and Bayesian computational method-based quantification of angiogenesis in the chick embryo model.
Singh G, Paik P · Anal Methods 2026
- Faricimab, a bispecific anti-VEGF/Ang-2 antibody, attenuates ovarian hyperstimulation syndrome in a rat model: correlation of ovarian VEGF immunostaining with serum VEGF.
Kirmaci Meric C, Tok OE, Kale I, et al. · J Ovarian Res 2026
Also in development for Hepatocellular Carcinoma
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- CadonilimabAK104Phase 331 trials
Akeso · Hepatocellular Carcinoma, Gastric / Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- SintilimabIBI308Phase 321 trials
Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma
- VolrustomigMEDI5752Phase 313 trials
AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer
- PF-08634404SSGJ-707Phase 312 trials
Pfizer · Non-Small Cell Lung Cancer, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung (NSCLC)
- FianlimabREGN3767Phase 311 trials
Regeneron · Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- TiragolumabMTIG7192A, RO7092284Phase 311 trials
Roche (Genentech) · Hepatocellular Carcinoma, Rectal Neoplasms, Rectal Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.